Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
4.650
+0.310 (7.14%)
Nov 4, 2024, 4:00 PM EST - Market closed

Fennec Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Revenue
48.8921.251.54-0.17-
Upgrade
Revenue Growth (YoY)
647.88%1284.50%----
Upgrade
Cost of Revenue
2.171.260.09---
Upgrade
Gross Profit
46.7219.991.45-0.17-
Upgrade
Selling, General & Admin
40.6432.7120.5112.2412.957.4
Upgrade
Research & Development
0.20.063.534.985.115.61
Upgrade
Operating Expenses
40.8532.7624.0417.2218.0613.01
Upgrade
Operating Income
5.87-12.77-22.59-17.22-17.89-13.01
Upgrade
Interest Expense
-4.03-3.68-1.13-0.14-0.41-0.06
Upgrade
Interest & Investment Income
0.980.440.20.050.090.32
Upgrade
Currency Exchange Gain (Loss)
-0.060.01-0.01-0.01--
Upgrade
Other Non Operating Income (Expenses)
------0.02
Upgrade
EBT Excluding Unusual Items
2.76-16.01-23.53-17.32-18.21-12.78
Upgrade
Gain (Loss) on Sale of Investments
-0.02-0.04-0.18-0.030.1-
Upgrade
Pretax Income
2.74-16.05-23.71-17.35-18.11-12.78
Upgrade
Net Income
2.74-16.05-23.71-17.35-18.11-12.78
Upgrade
Net Income to Common
2.74-16.05-23.71-17.35-18.11-12.78
Upgrade
Shares Outstanding (Basic)
272726262420
Upgrade
Shares Outstanding (Diluted)
292726262420
Upgrade
Shares Change (YoY)
7.70%1.14%1.03%9.71%19.14%5.04%
Upgrade
EPS (Basic)
0.10-0.60-0.90-0.67-0.76-0.64
Upgrade
EPS (Diluted)
0.10-0.60-0.90-0.67-0.76-0.64
Upgrade
Free Cash Flow
23.04-17.14-18.06-14.22-15.6-9.06
Upgrade
Free Cash Flow Per Share
0.81-0.65-0.69-0.55-0.66-0.46
Upgrade
Gross Margin
95.55%94.08%94.40%-100.00%-
Upgrade
Operating Margin
12.00%-60.09%-1471.60%--10520.59%-
Upgrade
Profit Margin
5.59%-75.50%-1544.89%--10652.35%-
Upgrade
Free Cash Flow Margin
47.13%-80.67%-1176.42%--9173.53%-
Upgrade
EBIT
5.87-12.77-22.59-17.22-17.89-13.01
Upgrade
EBIT Margin
12.00%-60.09%----
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.